Endometrial carcinoma (EC) is the most common gynaecologic malignancy in the United States and it is the fifth leading cause of cancer-related death in women ([@bib8]). Endometrioid adenocarcinomas (EAC) account for more than 80% of cases and tend to present as low-grade, early-stage tumours with favourable outcomes. Meanwhile, uterine serous carcinomas (USC) represent a minority (3--10%) of total endometrial cancer cases. They are usually high-grade tumours with deep myometrial invasion (MI), lymphovascular invasion (LVI), and a more aggressive clinical course ([@bib17]; [@bib1]; [@bib10]). Despite the validation of the prognostic value of a number of biomarkers in EC, clinicopathological factors such as tumour grade, stage, histological subtypes, LVI, and depth of MI are still considered as the most reliable prognostic parameters. High-grade tumour, advanced stage disease, presence of LVI, deep MI (outer third) and type II (USC and clear cell subtypes) endometrial adenocarcinoma constitute a high-risk group for recurrence and aggressive outcome in comparison to a low-risk group defined by low tumour grade, tumour confined to uterine corpus at presentation, absence of LVI, superficial MI (inner third), and type I (EAC and mucinous subtypes) endometrial adenocarcinoma ([@bib7]; [@bib9]; [@bib17]).

Pax8 is a member of the pair-box (PAX) family of transcription factor genes. It is important in the organogenesis of the thyroid, kidney, and mullerian tracts ([@bib18]; [@bib15]). Interestingly, Pax8 expression was found to be restricted to secretory cells of the fallopian tube epithelium, which most recently has been suggested as the cell of origin for serous ovarian carcinomas ([@bib2]). Otherwise, the interest in Pax8 in the reproductive tract has mainly focused on its use as a marker to distinguish carcinoma of gynaecologic origin *vs* carcinoma from other organs and from mesothelioma ([@bib16]; [@bib11], [@bib12]). The potential role of Pax8 in the endometrium has been rarely explored ([@bib3]). In this study, our aim is to define whether the expression of Pax8 protein in formalin-fixed samples from 229 patients correlated with disease outcome, such as recurrence rate, time to recurrence, and survival as well as with clinical--pathological factors such as tumour subtype, tumour grade and stage, LVI, depth of MI, and lymph node status.

Materials and Methods
=====================

Patient population
------------------

After obtaining Institutional Review Board (IRB) approval, pathology archives were searched for cases of endometrial malignant neoplasms from January 2000 to December 2010. A chart review was conducted with extraction of clinical information, including the patients\' age at the time of diagnosis, the surgical stage, the post-operative therapy, the recurrence-free survival (RFS), the disease-free survival (DFS), the site of recurrence, the cause and the time of death. All patients underwent a complete surgical staging procedure, including a total abdominal hysterectomy with bilateral salpingo-oophorectomy, pelving washing, with or without pelvic and para-aortic lymph node dissection depending on the tumour grade and the tumour subtypes. Patients were treated according to the National Comprehensive Cancer Network guidelines ([www.cancer.gov](http://www.cancer.gov)).

Histological evaluation
-----------------------

Tumour grade was assessed using the International Federation of Gynecology and Obstetrics (FIGO) system and by nuclear grading. The FIGO grading was determined as follows; tumours with \<5% solid areas were grade 1 (G1), tumours with 5--50% solid areas were grade 2 (G2) and tumours with \>50% solid areas were grade 3 (G3). Tumours nuclear grade was determined by the variation in nuclear size and shape, chromatin distribution, and size of the nucleoli. Tumour stage was assigned based on 1988 FIGO surgical staging guidelines ([@bib6]). All slides were examined by an expert gynaecologic pathologist for confirmation of the tumour type, tumour grade, depth of MI, presence of LVI and positive lymph nodes.

Four-*μ*m sections from formalin-fixed, paraffin-embedded tissues were processed for immunohistochemistry (IHC). Endogenous peroxidase was blocked with 0.3% hydrogen peroxidase for 5 min. Antigen retrieval was carried out in high citrate buffer for 3 min in a steam-cooker. Then, sections were incubated overnight with Pax8 antibody (monoclonal antibody, 1 : 400 dilutions; Biocare lab, San Francisco, CA, USA). A subsequent reaction was performed with the biotin-free HRP enzyme-labelled polymer of the Envision plus detection system (Dakocytomation, Carpinteria, CA, USA). Diaminobenzidine complex was used as the chromogen. Normal kidney and thyroid tissue were used as positive controls. In negative controls, a normal goat serum was used instead of the primary antibody resulting in a lack of detectable staining. Two pathologists (PMF and DS) reviewed the IHC slides on a double-headed microscope; only positive nuclear staining was considered positive and the staining intensity was interpreted as negative, weak, moderate, or strong. Both pathologists were unaware of the primary diagnosis. Only the staining intensity was taken into consideration for primary statistical analysis and it was divided into two groups; negative/weak was considered as negative (group I) and moderate/strong was considered as positive (group II).

Statistical analyses
--------------------

Statistical analyses were performed by R (<http://www.r-project.org/>). The clinical parameters used for modelling were age, tumour size, histological subtype, myometrial depth of invasion, LVI, FIGO grade, lymph nodes positive, recurrence, status, recurrence time, and survival time. Univariate and multivariate analysis was performed. To test the association between the biomarker and the clinical parameters, Fisher\'s exact test was performed for categorical parameters, and a logistic regression model was used for continuous parameters. For survival analysis, overall survival (OS) was censored at the time of last follow-up; events were death due to any cause. Disease-free survival (DFS) was censored at the time of last follow-up if disease progression did not occur; events were death due to any cause, disease relapse, and progression. Recurrence-free survival was censored at the time of last follow-up if the recurrence did not occur; events were death due to any cause and recurrence. The Kaplan--Meier method with log-rank test was used to calculate the cumulative survival time and check the OS, RFS, and DFS difference between the two different Pax8 groups. All reported *P*-values are two-sided. *P*-value was considered significant if *P*\<0.05.

Results
=======

The clinical and pathological features of 229 patients with endometrial adenocarcinoma are summarised in [Table 1](#tbl1){ref-type="table"}. The patients\' ages ranged from 29 to 97 years (median 65). Overall, 72% of cases were type I and 28% were type II subtype. In total, 42% of cases were FIGO G1, 20% G2, and 38% G3. As for tumour stage, 64% of cases were FIGO stage I, 14% stage II, 15% stage III, and 7% stage IV. Tumour size was considered as zero when no gross tumour was identified. In all, 65.5% of patients had lymph nodes dissection. Of these, 21.3% patients had positive lymph nodes and 78.6% had negative lymph nodes.

Univariate analysis of the distribution of clinical factors in relation to dichotomous status of Pax8 expression is illustrated in [Table 2](#tbl2){ref-type="table"}. There was a positive association between Pax8^+^ and high tumour grade (*P*=0.002), presence of LVI (*P*\<0.019), and type II tumour subtype (*P*\<0.0001). Serous and clear cell carcinomas as well as carcinosarcoma were more likely to express Pax8 than endometrioid adenocarcinomas. Pax8 expression is negatively associated with OS (*P*=0.0097) and DFS (*P*=0.019). However, these significant results were not found in multivariate analysis (data not shown).

Kaplan--Meier survival analysis was conducted. There was an association of Pax8 with OS (*P*=0.01486) with 5-year OS probability of 80.04% for patients with Pax8− and 55.9% for patients with Pax8^+^ ([Figure 1](#fig1){ref-type="fig"}). There was also an association of Pax8 and DFS probability (*P*=0.02028) with 5-year DFS probability of 72.12% for patients with Pax8− *vs* 49.88% for patients with Pax8^+^ expression ([Figure 2](#fig2){ref-type="fig"}). Finally an association of Pax8^+^ and shorter RFS was also seen (*P*=0.00203), with 74.36% for Pax8^−^ patients and 52.11% for Pax8^+^ patients ([Figure 3](#fig3){ref-type="fig"}).

Discussion
==========

The *Pax8* is located at the 2q13 chromosome band. It is a member of the pair-box family of genes that are required for the formation of several tissues from all germ layers in the mammalian embryo ([@bib18]; [@bib15]). Particularly, *Pax8* gene is essential for the organogenesis of the mullerian system, thyroid, and kidney. The biological significance of Pax8 protein expression in cancer is unknown, but recent studies suggest a possible role of Pax8 in tumourigenesis ([@bib4]; [@bib5]). In a previous study of human endometrial cancer samples, we found an upregulation of *Pax8* gene in advanced stage USC *vs* early stages USC (fold-change=1.44) and an upregulation of *Pax8* in USC with bad outcome *vs* USC with good outcomes (fold-change=1.72), although statistical significance was not reached (*P*\>0.05) possibly due to our small sample size (*n*=5) ([@bib13], [@bib14]). In this study, we sought to identify the expression and prognostic value of Pax8 protein expression in a large series of human endometrial cancer cases.

On univariate analysis, Pax8 protein-positive expression was associated with clinical and pathological predictive factors of poor outcome, such as high tumour grade, histological subtypes II, and presence of LVI. The association of Pax8 with tumour grade, and histologic type was seen in a previous study ([@bib3]). We also found that patients with tumours expressing Pax8 were more likely to die form disease. The 5-year OS probability for patients with Pax8^−^ was better than those with Pax8^+^ (80.04 *vs* 55.9%). Also, patients with Pax8^−^ have better 5-year DFS (72.12% for patients *vs* 49.88%) and better 5-year RFS (74.36% *vs* 52.11%) in comparison with those patients with Pax8^+^ tumours. These findings validate results of our prior study and provide evidence that overexpression of Pax8 protein could be a potential biomarker for poor outcome in patients with endometrial cancer.

Recently, Hahn and group showed an overexpression of Pax8 in numerous cancer cell lines, including ovarian and endometrial cancer ([@bib5]). In addition, when untested shRNAs against Pax8 were introduced to ovarian, kidney, and endometrial cancer cell lines, a drop in cell viability in cells that overexpressed Pax8 was noted, suggesting that inhibition of Pax8 activity could have a substantial impact on cancer treatment. Owing to high expression of Pax8 by type II tumours, which can be resistant to traditional chemotherapy, tailored targeted therapy to silence Pax8 could be a promising therapeutic option for these cases. Mechanistic studies are being conducted in our laboratory to define the role of Pax8 in cell culture.

In summary, our results indicate that endometrial cancer patients with tumours expressing Pax8^+^ have worse clinical outcomes compared with those with Pax8^−^. Pax8^+^ expression pattern is found to be negatively associated with 5-year OS, 5-year DFS, and 5-year RFS probabilities. These findings support the potential clinical utility of incorporating Pax8 IHC in the evaluation of endometrial cancer patients in order to identify those who are at higher risk of early recurrence. Silencing Pax8 could be the target of a new generation of therapeutic agents for selected patients.
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![Kaplan--Meier survival analysis revealed the association of Pax8 with overall survival (*P*=0.01486). The black curve is for Pax8^−^ patients and the grey curve is for Pax8^+^ patients. The 5-year overall survival probabilities for the Pax8^−^ and Pax8^+^ patients were 80.04 and 55.59%, respectively.](bjc2012241f1){#fig1}

![Kaplan--Meier survival analysis revealed the association of Pax8 with DFS probability (*P*=0.02028). The black curve is for Pax8^−^ patients and the grey curve is for Pax8^+^ patients. Five-year DFS probability of 72.12% for patients with Pax8^−^ *vs* 49.88% for patients with Pax8^+^ expression.](bjc2012241f2){#fig2}
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###### Clinical and pathological features of 229 patients with endometrial cancer

                                       **No. of cases**   **%**
  ------------------------------------ ------------------ -------
  No. of evaluable patients            229                 
                                                           
  *Age (years)*                                           
   Median                              65                  
   Range                               (29, 97)            
                                                           
  *Myometrial invasion (%)*                               
   Median                              30                  
   Range                               (0, 100)            
                                                           
  *Tumour size (cm)*                                      
   Median                              4                   
   Range                               (0, 33)             
                                                           
  *Tumour subtype*                                        
   Type II                             64                 28
   Type I                              165                72
                                                           
  *Grade FIGO*                                            
   1                                   96                 42
   2                                   46                 20
   3                                   87                 38
                                                           
  *Grade nuclear*                                         
   1                                   80                 35
   2                                   59                 26
   3                                   90                 39
                                                           
  *Recurrence*                                            
   No                                  177                77
   Persistent                          10                 4
   Progression                         3                  1
   Yes                                 39                 17
                                                           
  *Pax8 immunoexpression*                                 
   Negative                            158                69
   Positive                            71                 31
                                                           
  *LVI*                                                   
   No                                  161                70
   Yes                                 68                 30
                                                           
  *Tumour stage*                                          
   I                                   146                64
   II                                  31                 14
   III                                 35                 15
   IV                                  17                 7
                                                           
  *Lymph node positive*                                   
   Not applicable                      79                 34
   No                                  118                52
   Yes                                 32                 14
                                                           
  *Disease status*                                        
   Alive with no evidence of disease   159                69
   Alive with evidence of disease      19                 8
   Dead of unkown cause                1                  0
   Dead no evidence of disease         13                 6
   Dead of disease                     32                 14
   Dead with evidence of disease       4                  2
   Lost for follow-up                  1                  0

###### Univariate analysis of the association of Pax8 and the clinicopathological variate

                                                  **Pax8 negative**             **Pax8 positive**  ***P*****-value**   **Odds ratio**
  ------------------------------------ --------------------------------------- ------------------- ------------------- ----------------
  Age                                     63.04[a](#t2-fn2){ref-type="fn"}            69.58        0.0003              1.045435
  Tumour size                                           4.77                          4.29         0.3674              0.962615
  Myometrial invasion                                   40.95                         39.3         0.7384              0.998615
                                                                                                                        
  *Grade FIGO*                                         0.0024                       2.168619                           
   1                                    74 (46.84)[b](#t2-fn3){ref-type="fn"}      22 (30.99)                           
   2                                                 36 (22.78)                    10 (14.08)                           
   3                                                 48 (30.38)                    39 (54.93)                           
                                                                                                                        
  *Grade nuclear*                                      0.0006                                                          
   1                                                 66 (41.77)                    14 (19.72)                           
   2                                                 42 (26.58)                    17 (23.94)                           
   3                                                 50 (31.65)                    40 (56.34)                           
                                                                                                                        
  *Tumour stage*                                       0.3190                                                          
   I                                                 105 (66.46)                   41 (57.75)                           
   II                                                17 (10.76)                    14 (19.72)                           
   III                                               24 (15.19)                    11 (15.49)                           
   IV                                                 12 (7.59)                     5 (7.04)                            
                                                                                                                        
  *Tumour subtype*                                    \<0.0001                      0.256816                           
   Type II                                           30 (18.99)                    34 (47.89)                           
   Type I                                            128 (81.01)                   37 (52.11)                           
                                                                                                                        
  *Recurrence*                                         0.0363                       2.168619                           
   No                                                127 (85.81)                   50 (73.53)                           
   Yes                                               21 (14.19)                    18 (26.47)                           
                                                                                                                        
  *LVI*                                                0.0186                       2.099539                           
   No                                                119 (75.32)                   42 (59.15)                           
   Yes                                               39 (24.68)                    29 (40.85)                           
                                                                                                                        
  *Lymph node*                                          1.00                        1.070446                           
   No                                                72 (79.12)                    46 (77.97)                           
   Yes                                               19 (20.88)                    13 (22.03)                           
                                                                                                                        
  *Disease status*                                     0.0096                       2.364434                           
   Alive                                             131 (82.91)                   47 (67.14)                           
   Dead                                              27 (17.09)                    23 (32.86)                           
                                                                                                                        
  *Disease status*                                     0.0189                        2.07943                           
   Alive with no evidence of disease                 118 (74.68)                   41 (58.57)                           
   Others                                            40 (25.32)                    29 (41.43)                           

Continuous variables are tested by logistic regression and categorical variables are tested by the Fisher test.

Mean.

Count (%).
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